Volume 28, Number 10—October 2022
Research
SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA
Figure 2

Figure 2. Visualization of the fixed effects from the second Omicron emergence analysis on a log-odds scale (without age matching) in a study of SARS-CoV-2 vaccine breakthrough by Omicron and Delta variants, New York, USA. Odds scale in Appendix. Stratum-specific effects were often strong but were excluded for visual clarity. Increased values indicate an increased probability of infection with Omicron instead of Delta. Lines show ± 1 SE.
Page created: August 25, 2022
Page updated: September 20, 2022
Page reviewed: September 20, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.